Актуальные вопросы вакцинопрофилактики хронической обструктивной болезни легких в условиях современной клинической практики

45. Schwarz, T. F. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged >65 years / T. F. Schwarz, J. Flamaing, H. C. Rьmke, J. Penzes, C. Juergens, A. Wenz, D. Jayawardene, P. Giardina, E. A. Emini, W. C. Gruber, B. Schmoele-Thoma // Vaccine. 2011. Vol. 29, № 32. P. 5195-5202.

46. Shea, K. M. Rates of pneumococcal disease in adults with chronic medical conditions / K. M. Shea, J. Edelsberg, D. Weycker, R. A. Farkouh, D. R. Strutton, S. I. Pelton // Open Forum Infect. Dis. 2014. Vol. 1, № 1. P. ofu024.

47. S0gaard, M. Incidence and outcomes of patients hospitalized with COPD exacerbation with and without pneumonia / M. S0gaard, M. Madsen, A. L0kke, O. Hilberg, H. T. S0rensen, R. W. Thomsen // Int. J. Chron. Obstruct. Pulmon. Dis. 2016. № 11. P. 455-465.

48. Suaya, J. A. Post-hoc analysis of the 13-valent polysaccharide conjugate vaccine efficacy against vaccineserotype pneumococcal community acquired pneumonia in at-risk older adults / J. A. Suaya, Q. Jiang, D. A. Scott, W. C. Gruber, C. Webber, B. Schmoele-Thoma, C. K. Hall-Murray, L. Jodar, R. E. Isturiz // Vaccine. 2016. Vol. 36, № 11. P. 1477-1483.

49. Tomczyk, S. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged > 65 years: Recommendations of the Advisory Committee on Immunization Practices (ACIP) / S. Tomczyk, N.M. Bennett // Morb. Mortal. Wkly. Rep. 2014. Vol. 63, № 37. P. 824-826.

50. Van Hoek, A. J. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England / A. J. van Hoek, C. L. Sheppard, N. J. Andrews, P. A. Waight, M. P. Slack, T. G. Harrison, S. N. Ladhani, E. Miller // Vaccine. 2014. Vol. 32, № 34. P. 4349-4355.

51. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015 / GBD 2015 Disease and Injury Incidence and Prevalence Collaborators // Lancet. 2016. Vol. 388, № 10053. P. 1545-1602.

52. Walters, J. A. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease / J. A. Walters, S. Smith, P. Poole, R. H. Granger, R. Wood-Baker // Cochrane Database Syst. Rev. 2010. № 1. P. CD001390.

53. Walters, J. A. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease / J. A. Walters, J. N. Tang, P. Poole, R. Wood-Baker // Cochrane Database Syst. Rev. 2017. № 1. P. CD001390.

54. Wedzicha, J. A. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease / J. A. Wedzicha, S. E. Brill, J. P. Allinson, G. C. Donaldson // BMC Med. 2013. № 11. P. 181.

55. Wedzicha, J. A. COPD exacerbations: impact and prevention / J. A. Wedzicha, A. J. Mackay, R. Singh // Breathe. 2013. Vol. 9, № 6. P. 434-440.

56. World Health Organization. The top 10 causes of death. Режим доступа: http://www.who.int/mediacentre/factsheets/fs310/en, свободный. Заглавие с экрана. Яз. англ. Дата обращения: 31.12.2018.

57. Yawn, B. P. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis / B. P. Yawn, Y. Li, H. Tian, J. Zhang, S. Arcona, K. H. Kahler // Int. J. Chron. Obstruct. Pulmon. Dis. 2013. № 8. P. 295-304.

References

1. Gurevich K. G, Fesyun A. V., Svistunov O. P., Bondarenko V. V, Karazhelyaskov O. P. Skrytye voprosy ef- fektivnosti i bezopasnosti pnevmokokkovoy vaktsinatsii [Hidden issues of efficacy and safety of pneumococcal vaccination] Sistemnyy analiz i upravlenie v biomeditsinskikh sistemakh [System analysis and control in biomedical systems], 2013, vol. 12, no. 1, pp. 140-144.

2. Demko I. V, Korchagin E. E., Gordeeva N. V., Kraposhina A. Yu., Solov'eva I. A. Opyt vaktsinoprofilaktiki pnevmokokkovoy infektsii u vzroslykh na primere Krasnoyarskogo kraya [Experience of vaccine prophylaxis of pneumococcal infection in adults on the example of Krasnoyarsk region] Pul'monologiya [Pulmonology], 2017, vol. 27, no. 1, pp. 21-28. doi: 10.18093/0869-0189-2017-27-1-21-28.

3. Enikeev O. A. Osobennosti kletochnogo komponenta sistemnogo vospaleniya u patsientov s khronicheskoy obstruktivnoy bolezn'yu legkikh sredney i legkoy stepeni tyazhesti v stadii obostreniya[Features of the cellular component of systemic inflammation in patients with chronic obstructive pulmonary disease of moderate and mild severity in the acute stage]. Aspirantskiy vestnik Povolzh'ya [Post-graduate Bulletin of the Volga region], 2012, no. 5-6, pp. 35-40.

4. Zabolevaemost' naseleniya starshe trudosposobnogo vozrasta (s 55 let u zhenshchin i s 60 let u muzhchin) po Rossii v 2013 godu. Statisticheskie materialy. Chast' VII. [Morbidity of the population over the working age (from 55 years in women and 60 years in men) in Russia in 2013. Statistical data. Part VII.]. Available at: http://www.gks.ru/ (accessed 12 June 2018).

5. Ignatova G. L., Antonov V. N. Sozdanie regional'nykh programm vaktsinoprofilaktiki patsientov s khronicheskoy obstruktivnoy bolezn'yu legkikh na osnove kompleksnogo analiza effektivnosti vaktsinatsii [Creation of regional vaccination programs for patients with chronic obstructive pulmonary disease based on a comprehensive analysis of the effectiveness of vaccination.]. Consilium Medicum, 2016, no. 11, pp. 88-91.

6. Ignatova G. L., Antonov V. N., Rodionova O. V. Effektivnost' vaktsinoprofilaktiki kon"yugirovannoy pnevmokokkovoy vaktsinoy u bol'nykh khronicheskoy obstruktivnoy bolezn'yu legkikh za 3 goda [Efficacy of conjugate pneumococcal vaccine vaccination in patients with chronic obstructive pulmonary disease for 3 years.] Consilium Medicum, 2016, vol. 18, no. 3, pp. 42-46.

7. Issledovanie khronicheskikh respiratornykh zabolevaniy i faktorov riska v 12 regionakh Rossiyskoy Fed- eratsii [Study of chronic respiratory diseases and risk factors in 12 regions of the Russian Federation]. Available at: http://medi.ru/doc /60n0018.htm (accessed 4 March 2018).

8. Protasov A. D., Kostinov M. P., Zhestkov A. V, Shteyner M. L., Magarshak O. O., Kostinova T. A., Ryzhov A. A., Pakhomov D. V., Blagovidov D. A., Panina M. I. Vybor optimal'noy taktiki vaktsinatsii protiv pnevmokokkovoy infektsii s immunologicheskikh i klinicheskikh pozitsiy u patsientov s khronicheskoy obstruktivnoy bolezn'yu legkikh [Selection of optimal vaccination tactics against pneumococcal infection from immunological and clinical positions in patients with chronic obstructive pulmonary disease]. Terapevticheskiy arkhiv [Therapeutic archive], 2016, no. 5, pp. 62-69.

9. Federal'nye klinicheskie rekomendatsii po diagnostike i lecheniyu khronicheskoy obstruktivnoy bolezni leg- kikh. Rossiyskoe respiratornoe obshchestvo. Moskva 2018 [Federal clinical guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease. Russian respiratory society. Moscow 2018]. Available at: http://spulmo.ru/upload/federal_klinicheskie_rekomendaciy_hobl.pdf (accessed 15 April 2018).

10. Fedoseenko M. V Perspektiva vaktsinoprofilaktiki pnevmokokkovoy infektsii: sovremennyy vzglyad na problem [The prospect of vaccination of pneumococcal infection: a modern view of the problem]. Russkiy meditsinskiy zhurnal [Russian medical journal], 2009, vol. 17, no. 1, pp. 36-41.

11. Chuchalin A. G, Bilichenko T. N., Osipova G. L., Kurbatova E. A., Egorova N. B., Kostinov M. P. Vaktsino- profilaktika bolezney organov dykhaniya v ramkakh pervichnoy mediko-sanitarnoy pomoshchi naseleniyu [Vaccination of respiratory diseases in the framework of primary health care]. Pul'monologiya [Pulmonology], 2015, vol. 25, no. 2, pp. 4-19.

12. Chuchalin A. G, Briko N. I., Avdeev S. N., Belevskiy A. S., Shubin I. V, Kostinov M. P., Bilichenko T. N., Mishlanov V. Yu. Federal'nye klinicheskie rekomendatsii “Vaktsinoprofilaktika pnevmokokkovoy infektsii u vzroslykh” [Federal clinical guidelines “vaccine prophylaxis of pneumococcal infection in adults”]. Klinicheskie rekomendatsii [Clinical guidelines]. Moscow, 2018, 11 p.

13. Andreassen S. L., Liaaen E. D., Stenfors N., Henriksen A. H. Impact ofpneumonia on hospitalizations due to acute exacerbations of COPD.Clin Respir J, 2014, vol. 8, no. 1, pp. 93-99.

14. Andrews N. J., Waight P. A., George R. C., Slack M. P., Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine, 2012, vol. 30, no. 48, pp. 6802-6808.

15. Baxendale H. E., Johnson M., Keating S. M., Ashton L., Burbidge P., Woodgate S., Southern J., Miller E., Goldblatt E. Circulating pneumococcal specific plasma and memory B cells in the elderly two years after pneumococcal conjugate versus polysaccharide vaccination. Vaccine, 2010, vol. 28, no. 42, pp. 6915-6922.

16. Baxendale H. E., Keating S. M., Johnson M., Southern J., Miller E., Goldblatt D. The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly. Vaccine, 2010, vol. 28, no. 30, pp. 4763-4770.

17. Bonten M. J., Huijts S. M., Bolkenbaas M., Webber C., Patterson S., Gault S., van Werkhoven C. H., van Deursen A. M., Sanders E. A., Verheij T. J., Patton M., McDonough A., Moradoghli-Haftvani A., Smith H., Mellelieu T., Pride M. W., Crowther G, Schmoele-Thoma B., Scott D. A., Jansen K. U., Lobatto R., Oosterman B., Visser N., Caspers E., Smorenburg A., Emini E. A., Gruber W. C., Grobbee D. E. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N. Engl. J. Med., 2015, vol. 372, no. 12, pp. 1114-1125.

18. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly. Rep., 2012, vol. 61, no. 40, pp. 816-819.

19. Clutterbuck E. A., Lazarus R., Yu L. M., Bowman J., Bateman E. A. L., Diggle L., Angus B., Peto T. E., Beverley P. C., Mant D., Pollard A. J. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J. Infect. Dis., 2012, vol. 205, no. 9, pp. 1408-1416.

20. de Roux A., Schmцle-Thoma B., Schmцele-Thoma B., Siber G R., Hackell J. G, Kuhnke A., Ahlers N., Baker S. A., Razmpour A., Emini E. A., Fernsten P. D., Gruber W. C., Lockhart S., Burkhardt O., Welte T., Lode H. M. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin. Infect. Dis., 2008, vol. 46, no. 7, pp. 1015-1023.

21. Dransfield M. T., Harnden S., Burton R. L., Albert R. K., Bailey W. C., Casaburi R., Connett J., Cooper J. A., Criner G J., Curtis J. L., Han M. K., Make B., Marchetti N., Martinez F. J., McEvoy C., Nahm M. H., Niewoehner D. E., Porszasz J., Reilly J., Scanlon P. D., Scharf S. M., Sciurba F. C., Washko G R., Woodruff P. G., Lazarus S. C. Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin. Infect. Dis., 2012, vol. 55, no. 5, pp. e35-e44.

22. Esposito S., Bonanni P., Maggi S., Tan L., Ansaldi F., Lopalco P. L., Dagan R., Michel J. P., van Damme P., Gaillat J., Prymula R., Vesikari T., Mussini C., Frank U., Osterhaus A., Celentano L. P., Rossi M., Guercio V., Gavazzi G Recommended immunization schedules for adults: clinical practice guidelines by the ESCMID Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAIDID). Hum. Vaccin. Immunother., 2016, vol. 12, no. 7, pp. 1777-1794.

23. European Medicines Agency. CHMP variation assessment report [Prevenar 13]: type II variation EMEA/H/C/001104/n/0028 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001104/WC500n9784.pdf (accessed 1 October 2018).

24. European Respiratory Society. European Lung White Book. Lausanne, Switzerland: ERS / European Respiratory Society Available at: https://www.erswhitebook.org/files/public/Chapters/13_COPD.pdf (accessed 24 November 2018).

25. Falkenhorst G., Remschmidt C., Harder T., Hummers-Pradier E, Wichmann O., Bogdan C. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One, 2017, vol. 12, no. 1, pp. e0169368.

26. Fedson D., Guppy M. Pneumococcal vaccination of older adults: conjugate or polysaccharide? Hum. Vaccin. Immunother., 2013, vol. 9, no. 6, pp. 1382-1384.

27. Frenck R. W. Jr., Gurtman A., Rubino J., Smith W., van Cleeff M., Jayawardene D., Giardina P. C., Emini E. A., Gruber W. C., Scott D. A., Schmцle-Thoma B. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin. Vaccine. Immunol., 2012, vol. 19, no. 8, pp. 1296-1303.

28. Froes F., Roche N., Blasi F. Pneumococcal vaccination and chronic respiratory Diseases. International Journal of COPD, 2017, no. 12, pp. 3457-3468.

29. Furumoto A., Ohkusa Y, Chen M., Kawakami K., Masaki H., Sueyasu Y., Iwanaga T., Aizawa H., Nagatake T., Oishi K. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine, 2008, vol. 26, no. 33, pp. 4284-4289.

30. Grabenstein J. D., Manoff S. B. Pneumococcal vaccines in adults: assessing the evolving evidence. Vaccine, 2011, vol. 29, no. 37, pp. 6149-6154.

31. Grabenstein J. D., Manoff S. B. Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults. Vaccine, 2012, vol. 30, no. 30, pp. 4435-4444.

32. Greenberg D., Givon-Lavi N., Ben-Shimol S., Ziv J. B., Dagan R. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children < 5 years. Vaccine, 2015, vol. 33, no. 36, pp. 4623-4629.

33. Greenberg R. N., Gurtman A., Frenck R. W., Strout C., Jansen K. U., Trammel J., Scott D. A., Emini E. A., Gruber W. C., Schmoele-Thoma B. Sequental administration of 13-valent pneumococcal conjugatr vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naпve adults 60-64 years of age. Vaccine, 2014, vol. 32, no. 20, pp. 2364-2374.

34. Hak E., Grobbee D. E., Sanders E. A., Verheij T. J., Bolkenbaas M., Huijts S. M., Gruber W. C., Tansey S., McDonough A., Thoma B., Patterson S., van Alphen A. J., Bonten M. J. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth. J. Med, 2008, vol. 66, no. 9, pp. 378-383.

35. Tin Tin Htar M., Stuurman A. L., Ferreira G., Alicino C., Bollaerts K., Paganino C., Reinert R. R., Schmitt H. J., Trucchi C., Vestraeten T., Ansaldi F. Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PLoS One, 2017, vol. 12, no. 5, pp. e0177985.

36. Japanese Respiratory Society. Guidelines for diagnosis and management of COPD (chronic obstructive pulmonary disease), third edition: therapy and management. Suppl. COPD, 2009, pp. 70-144.

37. Kobayashi M., Bennett N. M., Gierke R., Almendares O., Moore M. R., Whitney C. G, Pilishvili T. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly. Rep., 2015, vol. 64, no. 34, pp. 944-947.

38. Kraicer-Melamed H., O'Donnell S., Quach C. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: a systematic review and meta-analysis.Vaccine, 2016, vol. 34, no. 13, pp. 1540-1550.

39. Laxminarayan R., Matsoso P., Pant S., Brower C., Rattingen J. A., Klugman K., Davies S. Access to effective antimicrobials: a worldwide challenge. Lancet, 2016, vol. 387, no. 10014, pp. 168-175.

40. Loo J. D., Conklin L., Fleming-Dutra K. E., Knoll M. D., Park D. E., Kirk J., Goldblatt D., O'Brien K. L., Whitney C. G Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization. Pediatr. Infect. Dis. J., 2014, vol. 33, suppl. 2, pp. 161-171.

41. Myint P. K., Lowe D., Stone R. A., Buckingham R. J., Roberts C. M. U.K. National COPD Resources and Outcomes Project 2008: patients with chronic obstructive pulmonary disease exacerbations who present with radiological pneumonia have worse outcome compared to those with non-pneumonic chronic obstructive pulmonary disease exacerbations. Respiration, 2011, vol. 82, no. 4, pp. 320-327.

42. Pneumococcal vaccines WHO position paper: 2012.Wkly. Epidemiol. Rec., 2012, vol. 87, no. 14, pp. 129-144.

43. Reinert R. R., Tasy B. Effectiveness of the 13-valent pneumococcal conjugate vaccine: Emerging data from invasive pneumococcal diseases, pneumonia, acute otitis media and nasopharyngeal carriage. Pediatricheskaya farma- kologiya [Pediatric Pharmacology], 2012, vol. 9, no. 3, pp. 8-11. doi: 10.15690/pf.v9i3.315.

44. Schmoele-Thoma B., Jackson L. A., Greenberg R. N., Frenck R., Gurtman A., Sundaraiyer V., Gruber W. C., Scott D. A., Isturiz R. E. Immunogenicity of 13-valent pneumococcal conjugate vaccine in immunocompetent older adults with stable underlying medical conditions. J. Vaccines. Immun., 2015, vol. 3, no. 2, pp. 7-12.

45. Schwarz T. F., Flamaing J., Rьmke H. C., Penzes J., Juergens C., Wenz A., Jayawardene D., Giardina P., Emini E. A., Gruber W. C., Schmoele-Thoma B. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged > 65 years. Vaccine, 2011, vol. 29, no. 32, pp. 5195-5202.

46. Shea K. M., Edelsberg J., Weycker D., Farkouh R. A., Strutton D. R., Pelton S. I. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect. Dis., 2014, vol. 1, no. 1, pp. ofu024.

47. S0gaard M., Madsen M., L0kke A., Hilberg O., S0rensen H. T., Thomsen R. W. Incidence and outcomes of patients hospitalized with COPD exacerbation with and without pneumonia. Int. J. Chron. Obstruct. Pulmon. Dis., 2016, no. 11, pp. 455-465.

48. Suaya J. A., Jiang Q., Scott D. A., Gruber W. C., Webber C., Schmoele-Thoma B., Hall-Murray C. K., Jodar L., Isturiz R. E. Post-hoc analysis of the 13-valent polysaccharide conjugate vaccine efficacy against vaccineserotype pneumococcal community acquired pneumonia in at-risk older adults. Vaccine, 2018, vol. 36, no. 11, pp. 1477-1483

49. Tomczyk S., Bennett N. M. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged > 65 years: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly. Rep., 2014, vol. 63, no. 37, pp. 824-826.

50. van Hoek A. J., Sheppard C. L., Andrews N. J., Waight P. A., Slack M. P., Harrison T. G, Ladhani S. N., Miller E. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine, 2014, vol. 32, no. 34, pp. 4349-4355.

51. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators.Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, 2016, vol. 388, no. 10053, pp. 1545-1602.

52. Walters J. A., Smith S., Poole P., Granger R. H., Wood-Baker R. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev., 2010, no. 11, pp. CD001390.

53. Walters J. A., Tang J. N., Poole P., Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst. Rev., 2017, no. 1, pp. CD001390.

54. Wedzicha J. A., Brill S. E., Allinson J. P., Donaldson G C. Mechanisms and impact of the frequent exacerba- tor phenotype in chronic obstructive pulmonary disease. BMC Med., 2013, no. 11, pp. 181.

55. Wedzicha J. A., Mackay A. J., Singh R. COPD exacerbations: impact andprevention. Breathe, 2013, vol. 9, no. 6, pp. 434-440.

56. World Health Organization. The top 10 causes of death. 2014. Available at: http://www.who.int/mediacentre/factsheets/fs310/en (accessed 31December 2016).

57. Yawn B. P., Li Y., Tian H., Zhang J., Arcona S., Kahler K. H. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int. J. Chron. Obstruct. Pulmon. Dis., 2013, no. 8, pp. 295-304.

Размещено на Allbest.ru